

## Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations

Iconovo AB (publ), which develops complete inhalation products for a global market, announces today that the U.S. Patent and Trademark Office has approved the company's application for design protection of the ICOcap® inhaler. Iconovo recently regained the global rights to sell and distribute ICOcap® from Stevanato Group and intends to intensify the marketing of the inhaler towards international pharmaceutical companies, while Stevanato Group will act as the exclusive contract manufacturer.

The design protection that the US Patent and Trademark Office has now issued for ICOcap® is valid until May 2037. The inhaler is already protected by patents in Europe. ICOcap® is one of several inhaler platforms that form the basis of Iconovo's customer offering in contract development management (CDMO). Earlier this year, a collaboration project was initiated with Kiox Pharma to develop a new treatment based on ICOcap® for a rare but serious lung disease.

"The fact that we have obtained strong exclusivity protection for ICOcap® in the world's largest pharmaceutical market further strengthens the offering for generating additional collaborative projects with international customers based on our unique inhaler. In addition, it broadens the opportunities for direct sales of the inhalers", says Roger Lassing, Vice President Business Development at Iconovo.

ICOcap® is a patented capsule-based dry powder inhaler with a one-piece-design making it easy to use. It has a robust, unique easy-to-grip design, a patented integrated mouthpiece cover, and low inhalation resistance. A standard version of ICOcap® is available off-the-shelf with the same function and performance as the established inhalers Breezhaler® from Novartis and RS01 from Berry.

### Contacts

---

**Johan Wäborg, CEO**

+46 707 78 51 71

[johan.waborg@iconovo.se](mailto:johan.waborg@iconovo.se)

### About Iconovo

---

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

### Attachments

---

[Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations](#)